Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV infection  

作　　者：Jing-Chun Song Hai-Tao Zhang Bin Liu Hui-Fang Sun 

机构地区：[1]Department of Infectious Diseases,Linxi Hospital,Kailuan General Hospital,Tangshan,Hebei Province,063000,China [2]Department of Hepatology,Tangshan City Hospital for Infectious Diseases,Tangshan,Hebei Province,063000,China [3]Department of Gastroenterology,Affiliated Hospital of North China University of Technology,Tangshan,Hebei Province,063000,China [4]Second Department of Internal Medicine,Tangshan Fourth Hospital,Tangshan,Hebei Province,063000,China

出　　处：《Journal of Hainan Medical University》2019年第8期36-40,共5页海南医学院学报（英文版）

摘　　要：Objective:To explore the Effects of alprostadil combined with nucleoside antiviral drugs on liver function, liver fibrosis markers and serum inflammatory factors in patients with decompensated liver cirrhosis with HBV infection.Methods: 136 patients with decompensated cirrhosis of HBV infection who were hospitalized in Linxi Hospital of Kailuan General Hospital, Tangshan Infectious Disease Hospital and North China University of Technology Hospital from January to February 2018, 2017 were selected. All patients were divided into control group and case group by random number table method, 68 cases in each group. The control group was treated with routine liver protection and antiviral therapy, while the case group was treated with alprostadil on the basis of the control group. The changes of liver function, liver fibrosis, liver and spleen imaging indexes, anti-virus related indexes and inflammatory factors were observed before and after treatment in the two groups.Results: The total effective rate of the case group was 97.06%, which was significantly higher than that of the control group (85.29%), and the difference was statistically significant. The ALT, AST, TBIL, LN, HA, PCIII, CIV, portal vein diameter, spleen vein diameter, spleen thickness, IL-6, hs-CRP, TNF-α and TGF-β1 were significantly lower in the case group than in the control group. ALB, HBV DNA conversion rate, HBsAg negative rate, and HBeAg negative rate were significantly higher than the control group, the difference was statistically significant. Conclusion: Alprostadil combined with nucleoside antiviral drugs can significantly improve the decompensation of HBV infection Liver function in patients with cirrhosis, reduce the degree of liver fibrosis, inhibit the production of serum inflammatory factors, and can effectively inhibit HBV replication, clinical efficacy is significant, with certain clinical application value.

关 键 词：ALPROSTADIL NUCLEOSIDE ANTIVIRAL drugs DECOMPENSATED cirrhosis LIVER function LIVER fibrosis 

分 类 号：R5[医药卫生—内科学]